12:00 AM
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ONYX-015: Phase II

Data from 30 evaluable patients showed an overall response of 63 percent for the combination of ONYX-015, cisplatin and 5-FU compared to a 35 percent historical chemotherapy response rate; 8 patients (27 percent) in the study had complete tumor regression...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >